Komatsu Takashi, Sato Yoshihiro, Tachibana Hideaki, Nakamura Motoyuki, Horiuchi Daisuke, Okumura Ken
Second Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.
Circ J. 2006 Jun;70(6):667-72. doi: 10.1253/circj.70.667.
There is little information on the selection of antiarrhythmic agents for long-term prevention of paroxysmal atrial fibrillation (PAF). In the present study the preventive effects of pilsicainide (Pil) and cibenzoline (Cib) were compared in patients with PAF that was defibrillated at <48 h or >or=48 h after onset.
A total of 60 patients (45 men, 15 women, mean age 66+/-10 years) were divided into 2 groups: Group I consisted of 22 patients in whom atrial fibrillation (AF) lasted for <48 h before cardioversion and Group II consisted of 38 patients in whom AF lasted for >or=48 h. A randomized, crossover protocol of treatment with Pil (150 mg/day) and Cib (300 mg/day) was used. Mean follow-up was 35+/-18 months. In Group I, the mean duration of maintenance of sinus rhythm was 12.3+/-2.9 months in patients treated with Pil, compared with 12.9+/-2.5 months in those givem Cib (p=NS between 2 groups). Actuarial event-free rates at 1, 3, 6, 12 months were 82%, 68%, 59% and 41%, respectively, in patients treated with Pil, and 91%, 77%, 68% and 50%, respectively, in those givenh Cib (p=NS between 2 groups). In Group II, the mean duration of maintenance of sinus rhythm was 1.6+/-0.5 months in patients treated with Pil, compared with 5.9+/-1.7 months in those given Cib (p<0.01). Actuarial event-free rates at 1, 3, 6, 12 months were 45%, 18%, 8% and 3%, respectively, in patients treated with Pil, and 63%, 45%, 29% and 16%, respectively, in those given Cib (p<0.05, at 12 months).
Prolonged tachycardia (>or=48 h) in patients with PAF seems to cause electrical remodeling. Cib, a multichannel blocker, is considered to be more effective in preventing the recurrence of PAF in the electrically remodeled atria than Pil, a pure sodium-channel blocker.
关于抗心律失常药物用于阵发性心房颤动(PAF)长期预防的选择方面的信息较少。在本研究中,比较了吡西卡尼(Pil)和西苯唑啉(Cib)对PAF发作后<48小时或≥48小时进行除颤的患者的预防效果。
总共60例患者(45例男性,15例女性,平均年龄66±10岁)被分为2组:第一组由22例在复律前房颤(AF)持续时间<48小时的患者组成,第二组由38例AF持续时间≥48小时的患者组成。采用了Pil(150毫克/天)和Cib(300毫克/天)的随机交叉治疗方案。平均随访时间为35±18个月。在第一组中,接受Pil治疗的患者窦性心律维持的平均持续时间为12.3±2.9个月,而接受Cib治疗的患者为12.9±2.5个月(两组之间p=无显著性差异)。接受Pil治疗的患者在1、3、6、12个月时的无事件发生率分别为82%、68%、59%和41%,而接受Cib治疗的患者分别为91%、77%、68%和50%(两组之间p=无显著性差异)。在第二组中,接受Pil治疗的患者窦性心律维持的平均持续时间为1.6±0.5个月,而接受Cib治疗的患者为5.9±1.7个月(p<0.01)。接受Pil治疗的患者在1、3、6、12个月时的无事件发生率分别为45%、18%、8%和3%,而接受Cib治疗的患者分别为63%、45%、29%和16%(在12个月时p<0.05)。
PAF患者的长时间心动过速(≥48小时)似乎会引起电重构。Cib作为一种多通道阻滞剂,被认为在预防电重构心房中PAF的复发方面比Pil(一种纯钠通道阻滞剂)更有效。